New stock news | China's leading CRO in non-clinical research field of cardiovascular and metabolic diseases, Ding Tai Pharmaceuticals, applied to the Hong Kong Stock Exchange.

According to the disclosure of the Hong Kong Stock Exchange on October 31, Jiangsu Dingtai Pharmaceutical Research (Group) Co., Ltd. (referred to as Dingtai Medicine) submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citigroup and Haitong Int'l as joint sponsors. According to the prospectus, Dingtai Medicine was established in 2008 and is a new type of Contract Research Organization (CRO) dedicated to providing integrated solutions based on disease biology for global pharmaceutical companies and research institutions. Through this business model, the company has surpassed the traditional role of CRO as an external service provider for undertaking fragmented tasks, and transformed into a strategic research and development partner for clients. The company provides comprehensive non-clinical safety, efficacy, drug metabolism and pharmacokinetics (DMPK) research, as well as integrated clinical trial services covering from concept verification to key trials, to provide clients with full lifecycle research and development support. During the reporting period, the company's majority of revenue came from providing non-clinical and clinical services, while revenue from providing research animals to third parties was minimal. The company focuses highly on clinical value and has accumulated deep expertise and experience in disease areas such as cardiovascular metabolism diseases, central nervous system (CNS) diseases, ophthalmology, autoimmune diseases, and oncology. According to Frost & Sullivan data, based on related income calculations by 2024, the company is the largest CRO in the non-clinical research field of cardiovascular metabolism diseases in China. According to Frost & Sullivan data, the company has built one of the most comprehensive sets of non-human primate (NHP) disease models in China, supporting key non-clinical research in various disease areas. With disease model projects, the company ranked as the third largest CRO in China's efficacy research field by related income calculations in 2024. The company's biomarker and translational medicine platform provide immunological, cellular, and molecular testing, supported by mass spectrometry bioanalysis with industry-leading sensitivity, robustness, and throughput characteristics. Meanwhile, the company proactively monitors the progress of new therapies in key disease areas to anticipate industry trends and strategically expand technological capabilities. The company has gained extensive project experience in nucleic acid therapy, monoclonal and bispecific antibodies, antibody-drug conjugates (ADC), and cell gene therapy (CGT) fields. New Approaches to Mul...